

IN THE CLAIMS:

Claims 14 through 18 are canceled herein. Claims 5-10, 12, and 13 have been amended herein. All of the pending claims 1 through 13 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1. (Original) A method for treating diabetes in a subject, said method comprising:
adminixing at least one phenserine compound or phenserine-like compound, and salts or esters thereof, and a pharmaceutically acceptable diluent, carrier or excipient to form a medicament; and
administering the medicament to the subject, thereby treating diabetes in said subject.
2. (Original) The method according to claim 1, wherein the phenserine compound is selected from the group consisting of (-)-N-phenylcarbamoyl eseroline, (3aS)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate; (-)-2'-methylphenylcarbamoyleseroline, (-)-2'-4'-dimethylphenylcarbamoyleseroline, (-)-4'-methylphenylcarbamoyleseroline, (-)-2'-ethylphenylcarbamoyleseroline, (-)-phenylcarbamoyleseroline, (-)-(-)-2',4',6'-trimethylphenylcarbamoyleseroline, (-)-2'-chlorophenylcarbamoyleseroline, (-)-2',6'-dichlorophenylcarbamoyleseroline, (-)-physovenol, (-)-5-O-(2'-methylphenylcarbamoyl)physovenol, (-)-3, 3a, 8, 8a-tetrahydro-3a, 8-dimethyl-2H-thieno-[2,3-b]indole-5-ol butyl carbamate, (-)-3, 3a, 8, 8a-tetrahydro-3a, 8-dimethyl-2H-thieno[2,3-b]indole-5-ol heptylcarbamate, (-)-3, 3a, 8, 8a-tetrahydro-3a, 8-dimethyl-2H-thieno[2,3-b]indole-5-ol phenylcarbamate, (-)-3, 3a, 8, 8a-tetrahydro-3a, 8-dimethyl-2H-thieno[2,3-b]indole-5-ol 2'-methylphenylcarbamate, (-)-3, 3a, 8, 8a-tetrahydro-3a, 8-dimethyl-2H-thieno[2,3-b]indole-5-ol 2'-isopropylphenylcarbamate, (-)-thiaphysovenine, (-)-Phenylthiaphysovenine, and (-)-2',4'-dimethylphenyl-thiaphysovenine.

3. (Original) The method according to claim 2, wherein the phenserine-like compound is selected from the group consisting of donepezil, galantamine, rivastigmine and tacrine.

4. (Original) The method according to claim 2, wherein the phenserine compound comprises (-)-N-phenylcarbamoyl eseroline or a salt or ester thereof.

5. (Currently amended) The method according to claim 1, ~~claim 2, claim 3 or claim 4~~, wherein treating diabetes comprises delaying onset of a cognitive impairment associated with diabetes.

6. (Currently amended) The method according to ~~any one of claims 1-5~~ claim 1, wherein treating diabetes comprises treating gestational diabetes.

7. (Currently amended) The method according to ~~any one of claims 1-6~~ claim 1, wherein treating diabetes comprises a prophylactic treatment of diabetes.

8. (Currently amended) The method according to ~~any one of claims 1-7~~ claim 1, wherein treating diabetes comprises treating cerebral angiopathy.

9. (Currently amended) The method according to ~~any one of claims 1-8~~ claim 1, wherein the subject is a human above the age of 60 years.

10. (Currently amended) The method according to ~~any one of claims 1-9~~ claim 1, further comprising administering said phenserine compound or phenserine-like compound prior to a meal.

11. (Original) The method according to claim 10, further comprising coadministering a hypoglycemic agent selected from the group consisting of a sulfonylurea, a meglitinide, a biguanide, a thiazolidinedione, an alpha-glucosidase inhibitor and mixtures thereof.

12. (Currently amended) The method according to ~~any one of claims 1-11~~ claim 1, wherein treating diabetes comprises treating at least one condition selected from the group consisting of hyperglycaemia, hypoglycaemia, response to hypoglycemic agents, diabetic neuropathy, diabetic retinopathy, kidney function, vascular dementia, ketone levels, hyperlipidaemia, and coronary artery disease.

13. (Currently amended) The method according to ~~any one of claims 1-5, 7, and 9-12~~ claim 1, wherein treating diabetes comprises treating insulin resistance.

14. through 18. (Canceled).